PMID- 23237765
OWN - NLM
STAT- MEDLINE
DCOM- 20131024
LR  - 20151119
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 22
IP  - 2
DP  - 2013 Mar
TI  - Use of pregabalin for nonconvulsive seizures and nonconvulsive status 
      epilepticus.
PG  - 116-8
LID - S1059-1311(12)00293-2 [pii]
LID - 10.1016/j.seizure.2012.11.004 [doi]
AB  - PURPOSE: To determine the efficacy of pregabalin (PGB) in treatment of frequent 
      nonconvulsive seizures (NCS) and nonconvulsive status epilepticus (NCSE) in 
      critically ill patients. METHODS: In this retrospective study, 21 patients were 
      identified as having received pregabalin for the treatment of NCS as determined 
      by continuous electroencephalographic monitoring. The patients were considered to 
      be responders if their seizures were terminated within 24h of initiation of PGB 
      without the addition of another antiepileptic agent. RESULTS: Of the 21 patients 
      who received PGB for treatment of NCS or NCSE, 11 (52%) were responders. PGB was 
      administered via a nasogastric tube or orally and was the 2nd to 4th agent used. 
      The average initial dose and total daily dose of PGB was similar in the 
      responders and non-responders (342mg vs. 360mg, respectively). PGB was more 
      effective in aborting NCS (9 patients, 82%) than NCSE (2 patients, 18%). Of the 9 
      brain tumor patients, PGB resulted in seizure cessation in 67% (6 patients). In 
      contrast, all patients with hypoxic injury (4) did not respond to PGB. The 
      responders were noted to have better clinical outcome (64% vs. 9% discharged 
      home). Most of the patients tolerated the medication without any significant 
      short term adverse effects, except two patients who were noted to have dizziness 
      and sedation. CONCLUSIONS: Pregabalin may be safe option for add-on treatment for 
      nonconvulsive seizures in critically ill patients when conventional therapy 
      fails.
CI  - Copyright (c) 2012 British Epilepsy Association. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Swisher, Christa B
AU  - Swisher CB
AD  - Department of Medicine (Neurology), Duke University Medical Center, Durham,NC 
      27710, United States.
FAU - Doreswamy, Meghana
AU  - Doreswamy M
FAU - Husain, Aatif M
AU  - Husain AM
LA  - eng
PT  - Journal Article
DEP - 20121211
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - 0 (Anticonvulsants)
RN  - 55JG375S6M (Pregabalin)
RN  - 56-12-2 (gamma-Aminobutyric Acid)
SB  - IM
MH  - Anticonvulsants/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pregabalin
MH  - Retrospective Studies
MH  - Seizures/*drug therapy/*epidemiology
MH  - Status Epilepticus/*drug therapy/*epidemiology
MH  - gamma-Aminobutyric Acid/*analogs & derivatives/therapeutic use
EDAT- 2012/12/15 06:00
MHDA- 2013/10/25 06:00
CRDT- 2012/12/15 06:00
PHST- 2012/09/07 00:00 [received]
PHST- 2012/11/07 00:00 [revised]
PHST- 2012/11/08 00:00 [accepted]
PHST- 2012/12/15 06:00 [entrez]
PHST- 2012/12/15 06:00 [pubmed]
PHST- 2013/10/25 06:00 [medline]
AID - S1059-1311(12)00293-2 [pii]
AID - 10.1016/j.seizure.2012.11.004 [doi]
PST - ppublish
SO  - Seizure. 2013 Mar;22(2):116-8. doi: 10.1016/j.seizure.2012.11.004. Epub 2012 Dec 
      11.